Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival …

Y Kawashima, T Fukuhara, H Saito… - The Lancet …, 2022 - thelancet.com
Background Bevacizumab is a promising candidate for combination treatment with
epidermal growth factor receptor tyrosine-kinase inhibitors (eg, erlotinib), which could …
被引用次数：75 相关文章

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival …

Y Kawashima, T Fukuhara, H Saito… - The Lancet …, 2021 - europepmc.org
Background Bevacizumab is a promising candidate for combination treatment with
epidermal growth factor receptor tyrosine-kinase inhibitors (eg, erlotinib), which could …

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival …

Y Kawashima, T Fukuhara, H Saito… - The Lancet …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Bevacizumab is a promising candidate for combination treatment with
epidermal growth factor receptor tyrosine-kinase inhibitors (eg, erlotinib), which could …

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival …

Y Kawashima, T Fukuhara, H Saito, N Furuya… - The Lancet Respiratory …, 2022 - Elsevier
Background Bevacizumab is a promising candidate for combination treatment with
epidermal growth factor receptor tyrosine-kinase inhibitors (eg, erlotinib), which could …
[PDF] academia.edu

[PDF][PDF] Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall …

Y Kawashima, T Fukuhara, H Saito, N Furuya… - 2021 - academia.edu
Background Bevacizumab is a promising candidate for combination treatment with
epidermal growth factor receptor tyrosine-kinase inhibitors (eg, erlotinib), which could …

[引用][C] Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall …

Y Kawashima, T Fukuhara, H Saito, N Furuya… - The Lancet Respiratory …, 2022 - cir.nii.ac.jp
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced,
metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an …